TrialScope Launches Free EudraCT Results Conversion Service

JERSEY CITY, N.J., April 7, 2015 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the availability of Convert, a free online clinical trial data conversion service. The complimentary service enables users to quickly and efficiently reuse clinical trial results data that was previously reported to the U.S. registry (clinicaltrials.gov) and convert it to the appropriate format for submission to the European registry (EudraCT).

Clinical trial sponsors face a looming deadline for reporting results in Europe. For eligible clinical trials that ended between July 21, 2013 and July 21, 2014, sponsors are required to post results by July 21, 2015. The data entry burden for only one study is significant and many sponsors have numerous study results to report. Sponsors can gain access to the free conversion service from the TrialScope website at convert.trialscope.com. 

TrialScope's Chief Strategy Officer, Thomas Wicks, commented, "TrialScope's complimentary EudraCT conversion service will provide sponsors with an opportunity to maintain compliance while simplifying the effort to do so. The service immediately reduces the data entry burden by as much as 85% for clinical trial results disclosures." 

Early feedback from users who previewed the service was very positive with one top pharma team rating the service 10 out of 10 for ease of use and speed. Another team estimated that they would save 5-8 hours per study on data entry alone using TrialScope's Convert service. 

Mike Forgash, CEO, TrialScope, added, "Our free EudraCT conversion service will help clinical trial sponsors realize time and resource savings not only by alleviating redundant data entry, but also by leveraging the quality assurance and review processes for data that has already been approved for disclosure in the U.S. The conversion will also ensure alignment of the data across registries, which is a significant compliance challenge for most global sponsors."